Antigen-expressing eDC line

CATALOG NUMBER · CR-C54-1

MD54.1
hTERT-expressing eDC line

A renewable human APC research tool expressing an hTERT fragment (aa 301–700) covering known HLA-A2.1- and HLA-A*24:02-restricted epitopes.

Overview

MD54.1 is an antigen-expressing eDC line designed for hTERT-related antigen presentation and T cell research. Its antigen construct, hTERT aa 301–700, covers known HLA-A2.1- and HLA-A*24:02-restricted epitopes, creating a defined starting configuration for testing an immune response.

Fragment coverage does not by itself establish processing, presentation or recognition of each covered epitope. These questions require peptide-specific and functional evidence in the relevant HLA setting.

All MD54 lines are typed HLA-A*02:01 / HLA-A*24:02. The series is therefore suitable for studying HLA-A*02:01- or HLA-A*24:02-restricted antigen presentation, and the MD54.1 fragment contains epitopes restricted by both alleles.

For drug target discovery, connect the APC configuration to an appropriate effector population and target cell model. HLA blockade, antigen controls and viability measurements help distinguish recognition from nonspecific changes in assay signals.

Technical specifications

AttributeCurrent information
Product name / catalog numberMD54.1 · hTERT-expressing eDC line · Cat. No. CR-C54-1
Antigen constructhTERT fragment (aa 301–700) covering known HLA-A2.1- and HLA-A*24:02-restricted epitopes; epitope list to be added
HLA typingHLA-A*02:01 / HLA-A*24:02
Cell systemHuman eDC line in an antigen-expressing configuration
Format & quantityTo be specified for MD54.1
Expression / presentation evidenceAntigen expression characterization and peptide-specific presentation evidence to be added
Quality documentationLine identity, mycoplasma testing, microbiological testing and culture performance documentation to be added for the offered material
Recommended passage windowTo be established from growth and functional characterization of the line

Growth conditions & culture development

MD54.1 culture support is being developed as a growth factor cocktail. The formulation must be evaluated for cell recovery, viability, growth, antigen expression and APC function across the intended culture interval.

Culture attributeDevelopment information
Basal medium referenceMD54 source line documentation lists RPMI 1640 with 10% FBS, or X-VIVO with 5% serum replacement. Final MD54.1 conditions remain to be confirmed.
Vessel & starting densitySource line reference: T25 flask; 0.5–1.5 × 106 cells/mL. These are development starting conditions, not a validated MD54.1 protocol.
Medium renewalSource line reference: approximately 2–3 times per week; optimize for the chosen cocktail and cell density trajectory.
Proposed growth factor cocktailIL-2-Fc4, IL-15SA-Fc4 and FLT3L-Fc4 are candidate components. Final composition, activity units, concentrations and feeding schedule are under development.
Growth patternAdherent growth is described for the MD54 source line family; assess morphology and recovery for the engineered MD54.1 configuration.
Handling & release documentationFinal instructions will define thawing, culture support, recovery, sampling and product-specific testing.
Under development

No optimized cocktail recipe or performance specification is presented here. Source line culture details guide development and must be verified for the antigen-expressing product.

Data & Figures

hTERT cytolysis data: U2OS target cells with or without TERT, and reduction of cytolysis with an HLA-A2.1 blocking antibodyDownload original figure

Figure 1 / Functional data

Testing antigen dependence and HLA restriction

In this hTERT research example, eDC-stimulated cytotoxic T lymphocytes were assessed against U2OS target cell models.

Antigen control
The upper panel compares U2OS-Luc and U2OS-Luc/TERT. The TERT-positive model is engineered to express HLA-A2.1 and TERT.
HLA control
The lower panel compares control antibody with HLA-A2.1 blockade against U2OS-Luc/TERT targets.
Readout
Percentage cytolysis across effector-to-target (E:T) ratios.
Interpretation
Higher cytolysis of the TERT-positive model and reduced cytolysis under HLA blockade are consistent with antigen-related, HLA-dependent activity. Confirm antigen and HLA status for both target variants before attributing the upper panel difference to antigen alone.
hTERT-associated target cell cytolysis. Source: CrossRelay research data. Original data image reproduced without alteration. Error bars and statistical symbols are retained; replicate counts and symbol definitions are not stated on this page. This research result is not a release specification for every eDC product.
hTERT study figure containing CD3, CD56 and CD8 flow cytometry panels, cytokine readouts and A549 target cytolysis

Original research data

Read phenotype and function together

This research study combines flow cytometry panels, cytokine readouts and target cell cytolysis. These measurements describe different parts of the response.

The cytolysis panel compares A549-Luc with A549-Luc/A2.1. A549 expresses endogenous hTERT; the target comparison therefore tests the added HLA context in this model.

A population phenotype alone does not establish antigen specificity. Interpret the target cell comparison together with the antigen and HLA controls shown in Figure 1.

hTERT research: immune phenotype and functional response. Source: CrossRelay research data. Original composite figure reproduced without alteration. Complete gating strategy, donor numbers, cytokine assay details and definitions of the error bars and statistical symbols are not stated on this page. These findings apply to the illustrated experiment.

Product documentation

DocumentStatus
MD54.1 product information sheetContent reserved
HLA typing and hTERT fragment specificationContent reserved
Culture & handling instructionsUnder development
Characterization and quality report for the lineContent reserved

Product documentation will distinguish configuration information from lot-specific testing. The research figures above are not an MD54.1 release certificate.

Publications

PNAS · 2018

Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells

Wu L, Zhang H, Jiang Y, Gallo RC, Cheng H. 115(19):E4453–E4462. DOI: 10.1073/pnas.1800550115.

View publication
Cancer Immunology, Immunotherapy · 2025

Cytotoxic lymphocytes induced by engineered human dendritic cells mediate potent anti-leukemia activity

Zhao C et al. 74:117. DOI: 10.1007/s00262-025-03971-y.

View publication

Selected publications provide scientific context. Consult the documentation for the specific eDC configuration when assessing product suitability.

Planning an hTERT experiment?

Discuss HLA compatibility, effector cells, targets and study controls.

Scientific support